Released Mar 10, 2026, after the close
10-K filed Mar 10, 2026, 69 days after period end · 0001628280-26-016394
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$14.44M-$14.44M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$14,895,544N/M
Operating Cash Flowderived-$9,766,487N/M
Free Cash Flowderived-$9,766,487N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$14.44M | -$9.75M | -$4.42M | -$9.89M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR